Drug that delays onset of type 1 diabetes approved in England and Wales (opens original article in a new tab)

The NHS in England and Wales has approved teplizumab, the first drug to delay type 1 diabetes onset, offering patients up to three years of delayed symptoms without curing the disease. The treatment is available for those with early-stage type 1 diabetes and marks a significant advancement in diabetes care.

• The first drug to delay type 1 diabetes onset, teplizumab, is approved for NHS use in England and Wales
• Teplizumab delays onset for up to three years but does not cure diabetes
• The drug is available for adults and children aged eight and above with early-stage type 1 diabetes
• NHS approved teplizumab after evaluating clinical benefits and cost-effectiveness